MagForce AG participates in four upcoming international conferences in Q4 2016

Berlin, Germany and Nevada, USA, October 27, 2016 - MagForce AG (Frankfurt, Entry Standard, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today announced its participation in four upcoming scientific and investor conferences in the fourth quarter 2016:

- **13th AIO Autumn Convention - Oncology in Internal Medicine Working Group (AIO) – Update Medical Oncology**
  Date: November 17-19, 2016
  Location: Berlin, Germany
  Booth: No. 24, level 1

- **21st Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO)**
  Date: November 17-20, 2016
  Location: Scottsdale, Arizona, USA
  Presentation: “Inflammatory response after modified NanoTherm® and radiotherapy of recurrent glioblastoma”
  Presenter: Team of Prof. Dr. med. Walter Stummer, Director of the Clinic for Neurosurgery, University Hospital Münster
  Speaker: Dr. Dr. med. Oliver Grauer, Head of Neuro-Oncology Team, University Hospital Münster
  Date of presentation: Friday, November 18, 2016; Poster session 19:00 MST

- **German Equity Forum**
  Date: November 21-23, 2016
  Location: Frankfurt, Germany
  Presentation: Ben J. Lipps, CEO of MagForce AG, Monday, November 21, 2016, 14:00 CET
  Room: Oslo

- **NOA Winter School 2016 – Neurological Working Group**
  Date: December 1-2, 2016
  Location: Münster, Germany
  Presentation: “Local Hyperthermia as an adjuvant for malignant glioblastoma – NanoTherm and NanoPaste”
  Speaker: Dr. med. Johannes Wölfer, Deputy Director of the Neurosurgical Department, Clinic and Policlinic for Neurosurgery, University Hospital Münster
  Date of presentation: Thursday, December 1, 2016, 15:00 CET
About MagForce AG and MagForce USA, Inc.

MagForce AG, listed in the entry standard of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm™ therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. Mithril Capital Management, a growth-stage technology fund founded by Ajay Royan and Peter Thiel, along with MagForce AG, are investors and strategic partners in MagForce USA, Inc.

NanoTherm™, NanoPlan®, and NanoActivator® are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm™, NanoPlan, and NanoActivator® are trademarks of MagForce AG in selected countries.

For more information, please visit: www.magforce.com

Get to know our Technology: video (You Tube)

Stay informed and subscribe to our mailing list

For meeting arrangements or any further questions, please contact us at:

<table>
<thead>
<tr>
<th>Patient Advocacy</th>
<th>Medical Liaison</th>
<th>Media &amp; Investors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Katarzyna Zarychta</td>
<td>Dr. Ulrike Boettcher</td>
<td>Barbara v. Frankenberg</td>
</tr>
<tr>
<td>+49 30 30 83 80-66</td>
<td>+49 89 95 477 95-64</td>
<td>+49 30 30 83 80-77</td>
</tr>
<tr>
<td><a href="mailto:kzarychta@magforce.com">kzarychta@magforce.com</a></td>
<td><a href="mailto:uboettcher@magforce.com">uboettcher@magforce.com</a></td>
<td><a href="mailto:bfrankenberg@magforce.com">bfrankenberg@magforce.com</a></td>
</tr>
</tbody>
</table>

Disclaimer

This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.